The author of today’s article made a mistake when they previously went against their rules for trading a premium-priced biotech and jumped on a small-cap pharmaceutical stock focused on women’s health issues. Now, however, they see the stock as presenting a great contrarian opportunity. Here’s some of what they have to say: “The company had a rough time with the COVID-19 pandemic, but I believe it is primed to make a strong resurgence as the country opens up and the women’s health industry returns to normal operations.” For more, CLICK HERE.